Can CRC tumor microenvironments be sorted into useful subtypes?
Multi-omics CCCRC typing splits colorectal cancers into proliferative (C1), immunosuppressed (C2), immune-excluded (C3), and immunomodulatory (C4) TME classes with different therapy leads.
Source
Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis
Study at a glance
- Design
- Computational / modelling — Integrative multi-omics + AI spatial WSI analysis defining CCCRC TME subtypes
- N
- N=1471 · 1471 CRC patients in CRC-AFFY cohort heatmap; 725 in CRC-RNAseq cohort
- Population
- Colorectal cancer bulk/multi-omics cohorts with TME signature profiling
- Outcome
- Four CCCRC TME subtypes with distinct therapy/prognosis implications
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Can CRC tumor microenvironments be sorted into useful subtypes?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
61 TME-related signatures formed the TME panel.
a total of 61 TME-related signatures were collected to form the TME panel
Heatmap analyses included 1471 CRC-AFFY patients.
Heatmap of 1471 colorectal cancer (CRC) patients
What they did
Built a 61-signature TME panel, integrated multi-omics CRC cohorts, and used AI-enabled spatial whole-slide analysis to define CCCRC subtypes, then linked subtypes to histology, molecular features, treatment sensitivity, prognosis, and a simple gene classifier.
What they found
C1 is proliferative/low immunogenicity (chemo + cetuximab candidate); C2 is immunosuppressed/terminally exhausted (chemo + bevacizumab candidate); C3 is stromal/immune-excluded (WNT inhibitor WIKI4 sensitivity); C4 is immunomodulatory (immune checkpoint blockade candidate).
The limits
What it doesn't show
Subtype–therapy matches are hypothesis-generating from observational/computational data, not randomized treatment trials.
Key terms
- TME
- Tumor microenvironment of immune, stromal, and metabolic compartments.
- CCCRC
- Comprehensive characterization of CRC TME subtype system in this paper.
- Immune-excluded
- Stromal upregulation with poor T-cell infiltration into the tumor core.
- Immunomodulatory
- TME with upregulated anti-tumor immune components.
- Gene classifier
- Simple gene set used to assign CCCRC subtype.
Flashcards
0 of 9 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
How many CCCRC subtypes were defined?
Common questions
How many subtypes?
Four CCCRC subtypes (C1–C4).
C4 therapy angle?
Potential immune checkpoint blockade candidate.
TME panel size?
61 TME-related signatures.
Large AFFY cohort N?
1471 CRC patients.
More on cancer-biology